BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, January 11, 2026
Home » Authors » Nuala Moran

Nuala Moran

Articles

ARTICLES

Biogen Idec Forms Parkinson's Deal With Vernalis For $100M

June 25, 2004
By Nuala Moran

Biogen Idec Forms Parkinson's Deal With Vernalis For $100M

June 25, 2004
By Nuala Moran

Planning Phase III, Onyvax Mulling Financing Options

June 23, 2004
By Nuala Moran

Planning Phase III, Onyvax Mulling Financing Options

June 23, 2004
By Nuala Moran

FBI: Biotech Industry Not Facing Serious Problem' Of Extremists

June 21, 2004
By Nuala Moran

Strakan, ProSkelia Merging, Building 'Company To Last'

June 16, 2004
By Nuala Moran

Vectura, Evolutec File To Try IPO Luck On London Market

June 16, 2004
By Nuala Moran
LONDON - There are further signs that the UK's initial public offering drought might be nearing an end, as Vectura Ltd. and Evolutec Group plc announced plans to float on London's Alternative Investment Market, looking for £20 million to £25 million (US$32.3 million to US$45.3 million) and £7.5 million, respectively. (BioWorld International)
Read More

Vectura, Evolutec File To Try IPO Luck On London Market

June 16, 2004
By Nuala Moran
LONDON - There are further signs that the UK's initial public offering drought might be nearing an end, as Vectura Ltd. and Evolutec Group plc announced plans to float on London's Alternative Investment Market, looking for £20 million to £25 million (US$32.3 million to US$45.3 million) and £7.5 million, respectively. (BioWorld International)
Read More

Strakan, ProSkelia Merging, Building 'Company To Last'

June 16, 2004
By Nuala Moran

Cancer Researchers Continue Radioimmunotherapy Exploration

June 11, 2004
By Nuala Moran
View All Articles by Nuala Moran

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 9, 2026.
  • 3D rendering of antibody drug conjugated with cytotoxic payload

    ADCs’ breakout 2025 and their still-unfinished potential

    BioWorld Science
    Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
  • CAR T cell attacking cancer cells

    Development and characterization of anti-CD19 in vivo CAR T therapy

    BioWorld Science
    Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
  • Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome

    BioWorld Science
    The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing